John Deanfield

Aug 24, 2024 | thelancet.com | Maria Byrne |John Deanfield |Subodh Verma

Evidence before this studyHeart failure is more common in patients with overweight or obesity than in the general population and is typically heart failure with preserved ejection fraction, which has had few treatment options until recently.

Jul 1, 2024 | digitalcommons.library.tmc.edu | Donna Ryan |Ildiko Lingvay |John Deanfield |Steven Kahn

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.

Nov 11, 2023 | nejm.org | A. Michael Lincoff |Helen M. Colhoun |John Deanfield |Scott Emerson

AbstractSemaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.